5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮

用途

Symadex, also known as imidazoacridone; XLS-002 and C-1311, is a member of the novel imidazoacridinone family of anticancer agents. Imidazoacridone has shown activity in experimental tumour models both in vitro and in nude mice. C-1311 at the EC(99) dose delayed progression of cells through the S phase which was followed by G2 arrest. C-1311 does not induce rapid apoptosis in HT-29 cells, instead drug exposure leads to prolonged G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe.

名称

[ CAS 号 ]:
138154-39-9

[ 中文名 ]:
5-((2-(二乙基氨基)乙基)氨基)-8-羟基-6H-咪唑并[4,5,1-de]吖啶-6-酮

[ 英文名 ]:
C-1311

[英文别名 ]:

C 1311
XLS-002

物理化学性质

[ 密度 ]:
1.32g/cm3

[ 沸点 ]:
605.8ºC at 760mmHg

[ 分子式 ]:
C₂₀H₂₂N₄O₂

[ 分子量 ]:
350.41400

[ 闪点 ]:
320.2ºC

[ 精确质量 ]:
350.17400

[ PSA ]:
69.87000

[ LogP ]:
2.97100

[ 蒸汽压 ]:
2.86E-15mmHg at 25°C

[ 折射率 ]:
1.68

安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 危险品运输编码 ]:
NONH for all modes of transport

合成路线

详细合成路线

上下游产品

上游产品

下游产品

文献

DNA-damaging imidazoacridinone C-1311 induces autophagy followed by irreversible growth arrest and senescence in human lung cancer cells.

J. Pharmacol. Exp. Ther. 346(3) , 393-405, (2013)

Imidazoacridinone 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. In this study, we describe the uni...

Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Drug Metab. Dispos. 41(2) , 414-21, (2013)

The acridinone derivates 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) are promising antitumor agents with high activ...

Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.

J. Pharm. Biomed. Anal. 39(1-2) , 46-53, (2005)

C1311 (5-[[2-(diethylamino)ethyl]amino]-8-hydroxyimidazo [4,5,1-de]-acridin-6-one-dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a novel group of rationally des...

更多文献